Skip to main content

Advertisement

SpringerLink
Log in

Analysis of progression and recurrence of meningioma using 11C-methionine PET

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The recurrence rate of meningioma after surgery is high, and progression is often observed. The risk factors for recurrence and progression are not clear. We evaluated the risk factors for recurrence and progression in meningioma using 11C-methionine (MET) positron emission tomography (PET).

Methods

Thirty-seven patients (mean follow-up, 80 months) with an intracranial meningioma were enrolled. MET PET was performed before treatment between 1995 and 2010, and patients were followed up in an out-patient clinic. Surgery was performed in 33 patients, and a wait-and-see approach was taken in four patients. We evaluated the extent of tumor resection, location, WHO grade, Ki-67 labeling index, and lesion to normal ratio (LN ratio) of MET uptake.

Results

Six of the surgical cases had a recurrence, and two of the observation-only patients had tumor progression. A high LN ratio of MET uptake was a significant risk factor for recurrence and progression with univariate analysis. The area under the curve of receiver operating characteristic curve for the LN ratio of MET uptake was 0.754, and the optimal cutoff value was 3.18 (sensitivity 63 %, specificity 79 %). With multivariate analysis, a high LN ratio of MET uptake, non-gross total resection, and a high WHO grade were significant risk factors for progression and recurrence.

Conclusion

A high LN ratio of MET uptake was a risk factor for tumor progression and recurrence. The advantage of MET PET is that it is not invasive and can easily be used to evaluate the whole tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (1984-2000) Neurol Med Chir. 2009;49 Suppl.

  2. Crompton MR, Gautier-Smith PC. The prediction of recurrence in meningiomas. J Neurol Neurosurg Psychiatry. 1970;33(1):80–7.

    Article  PubMed  CAS  Google Scholar 

  3. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol. 1975;208(4):279–98.

    Article  PubMed  CAS  Google Scholar 

  4. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir. 2004;146(1):37–44 (discussion).

    Article  PubMed  CAS  Google Scholar 

  5. McCarthy BJ, Davis FG, Freels S, Surawicz TS, Damek DM, Grutsch J, et al. Factors associated with survival in patients with meningioma. J Neurosurg. 1998;88(5):831–9.

    Article  PubMed  CAS  Google Scholar 

  6. Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The natural history of incidental meningiomas. Neurosurgery. 2003;53(1):62–70 (discussion-1).

    Article  PubMed  Google Scholar 

  7. Niiro M, Yatsushiro K, Nakamura K, Kawahara Y, Kuratsu J. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry. 2000;68(1):25–8.

    Article  PubMed  CAS  Google Scholar 

  8. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T. Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev. 2006;29(4):293–6 discussion 296-297.

    Article  PubMed  Google Scholar 

  9. Kuratsu J, Kochi M, Ushio Y. Incidence and clinical features of asymptomatic meningiomas. J Neurosurg. 2000;92(5):766–70.

    Article  PubMed  CAS  Google Scholar 

  10. Alvernia JE, Dang ND, Sindou MP. Convexity meningiomas: study of recurrence factors with special emphasis on the cleavage plane in a series of 100 consecutive patients. J Neurosurg. 2011;115(3):491–8.

    Article  PubMed  Google Scholar 

  11. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg. 2010;112(5):925–33.

    Article  PubMed  Google Scholar 

  12. Guevara P, Escobar-Arriaga E, Saavedra-Perez D, Martinez-Rumayor A, Flores-Estrada D, Rembao D, et al. Angiogenesis and expression of estrogen and progesterone receptors as predictive factors for recurrence of meningioma. J Neurooncol. 2010;98(3):379–84.

    Article  PubMed  CAS  Google Scholar 

  13. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, et al. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol. 1996;91(5):504–10.

    Article  PubMed  CAS  Google Scholar 

  14. Takeuchi H, Kubota T, Kabuto M, Kitai R, Nozaki J, Yamashita J. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study. Surg Neurol. 1997;48(5):501–6.

    Article  PubMed  CAS  Google Scholar 

  15. Lanzafame S, Torrisi A, Barbagallo G, Emmanuele C, Alberio N, Albanese V. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up. Pathol Res Pract. 2000;196(7):483–8.

    Article  PubMed  CAS  Google Scholar 

  16. Adegbite AB, Khan MI, Paine KW, Tan LK. The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg. 1983;58(1):51–6.

    Article  PubMed  CAS  Google Scholar 

  17. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62(1):18–24.

    Article  PubMed  CAS  Google Scholar 

  18. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92(6):1541–9.

    Article  PubMed  CAS  Google Scholar 

  19. Torii K, Tsuyuguchi N, Kawabe J, Sunada I, Hara M, Shiomi S. Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas. Ann Nucl Med. 2005;19(8):677–83.

    Article  PubMed  Google Scholar 

  20. Kim S, Chung JK, Im SH, Jeong JM, Lee DS, Kim DG, et al. 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2005;32(1):52–9.

    Article  PubMed  CAS  Google Scholar 

  21. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. AJNR Am J Neuroradiol. 2008;29(10):1867–71.

    Article  PubMed  CAS  Google Scholar 

  22. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36(10):1574–82.

    Article  PubMed  Google Scholar 

  23. Lippitz B, Cremerius U, Mayfrank L, Bertalanffy H, Raoofi R, Weis J, et al. PET-study of intracranial meningiomas: correlation with histopathology, cellularity and proliferation rate. Acta Neurochirurgica Suppl. 1996;65:108–11.

    CAS  Google Scholar 

  24. Tsuyuguchi N. Kinetic analysis of glucose metabolism by FDG-PET versus proliferation index of Ki-67 in meningiomas–comparison with gliomas. Osaka City Med J. 1997;43(2):209–23.

    PubMed  CAS  Google Scholar 

  25. Cremerius U, Bares R, Weis J, Sabri O, Mull M, Schroder JM, et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med. 1997;38(1):26–30.

    PubMed  CAS  Google Scholar 

  26. Iuchi T, Iwadate Y, Namba H, Osato K, Saeki N, Yamaura A, et al. Glucose and methionine uptake and proliferative activity in meningiomas. Neurol Res. 1999;21(7):640–4.

    PubMed  CAS  Google Scholar 

  27. Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergstrom M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-l-methionine PET. Eur J Nucl Med. 2000;27(12):1793–9.

    Article  PubMed  CAS  Google Scholar 

  28. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99(2):217–25.

    Article  PubMed  CAS  Google Scholar 

  29. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30(6):868–73.

    Article  PubMed  CAS  Google Scholar 

  30. Arita H, Kinoshita M, Okita Y, Hirayama R, Watabe T, Ishohashi K, et al. Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography. J Neurooncol. 2012;107(2):379–86.

    Article  PubMed  Google Scholar 

  31. Abe Y, Matsuzawa T, Itoh M, Ishiwata K, Fujiwara T, Sato T, et al. Regional coupling of blood flow and methionine uptake in an experimental tumor assessed with autoradiography. Eur J Nucl Med. 1988;14(7–8):388–92.

    PubMed  CAS  Google Scholar 

  32. Kimura H, Takeuchi H, Koshimoto Y, Arishima H, Uematsu H, Kawamura Y, et al. Perfusion imaging of meningioma by using continuous arterial spin-labeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. AJNR Am J Neuroradiol. 2006;27(1):85–93.

    PubMed  CAS  Google Scholar 

  33. Siegers HP, Zuber P, Hamou MF, van Melle GD, de Tribolet N. The implications of the heterogeneous distribution of Ki-67 labelled cells in meningiomas. Br J Neurosurg. 1989;3(1):101–7.

    Article  PubMed  CAS  Google Scholar 

  34. Abramovich CM, Prayson RA. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas. Arch Pathol Lab Med. 1999;123(9):793–800.

    PubMed  CAS  Google Scholar 

  35. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27(2):114–20.

    Article  PubMed  Google Scholar 

  36. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W. Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Archiv. 2006;449(5):529–38.

    Article  PubMed  CAS  Google Scholar 

  37. Moller ML, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry. J Neurooncol. 1997;34(3):241–6.

    Article  PubMed  CAS  Google Scholar 

  38. Nakaguchi H, Fujimaki T, Matsuno A, Matsuura R, Asai A, Suzuki I, et al. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry. Cancer. 1999;85(10):2249–54.

    Article  PubMed  CAS  Google Scholar 

  39. Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol. 1998;29(12):1420–7.

    Article  PubMed  CAS  Google Scholar 

  40. Kolles H, Niedermayer I, Schmitt C, Henn W, Feld R, Steudel WI, et al. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics. Acta Neurochir. 1995;137(3–4):174–81.

    Article  PubMed  CAS  Google Scholar 

  41. Langford LA, Cooksley CS, DeMonte F. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas. Hum Pathol. 1996;27(4):350–4.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors appreciate the technical support of the radiological technologist at our institute.

Conflict of interest

The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

    Hidetoshi Ikeda, Naohiro Tsuyuguchi, Noritsugu Kunihiro, Kenichi Ishibashi, Takeo Goto & Kenji Ohata

Authors
  1. Hidetoshi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naohiro Tsuyuguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Noritsugu Kunihiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kenichi Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeo Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Ohata
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidetoshi Ikeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ikeda, H., Tsuyuguchi, N., Kunihiro, N. et al. Analysis of progression and recurrence of meningioma using 11C-methionine PET. Ann Nucl Med 27, 772–780 (2013). https://doi.org/10.1007/s12149-013-0747-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-013-0747-z

Keywords

Search

Navigation